500 related articles for article (PubMed ID: 23146137)
1. Immunological basis of melanoma-associated vitiligo-like depigmentation.
González R; Torres-López E
Actas Dermosifiliogr; 2014 Mar; 105(2):122-7. PubMed ID: 23146137
[TBL] [Abstract][Full Text] [Related]
2. Autoimmunity as an aetiological factor in vitiligo.
Rezaei N; Gavalas NG; Weetman AP; Kemp EH
J Eur Acad Dermatol Venereol; 2007 Aug; 21(7):865-76. PubMed ID: 17658994
[TBL] [Abstract][Full Text] [Related]
3. The antibody response against MART-1 differs in patients with melanoma-associated leucoderma and vitiligo.
Teulings HE; Willemsen KJ; Glykofridis I; Krebbers G; Komen L; Kroon MW; Kemp EH; Wolkerstorfer A; van der Veen JP; Luiten RM; Tjin EP
Pigment Cell Melanoma Res; 2014 Nov; 27(6):1086-96. PubMed ID: 25043574
[TBL] [Abstract][Full Text] [Related]
4. Monobenzone-induced depigmentation: from enzymatic blockade to autoimmunity.
van den Boorn JG; Melief CJ; Luiten RM
Pigment Cell Melanoma Res; 2011 Aug; 24(4):673-9. PubMed ID: 21689385
[TBL] [Abstract][Full Text] [Related]
5. Melanocyte-specific, cytotoxic T cell responses in vitiligo: the effective variant of melanoma immunity?
Garbelli S; Mantovani S; Palermo B; Giachino C
Pigment Cell Res; 2005 Aug; 18(4):234-42. PubMed ID: 16029417
[TBL] [Abstract][Full Text] [Related]
6. Reactivity to tyrosinase: expression in cancer (melanoma) and autoimmunity (vitiligo).
Merimsky O; Shoenfeld Y; Baharav E; Zigelman R; Fishman P
Hum Antibodies Hybridomas; 1996; 7(4):151-6. PubMed ID: 9140726
[TBL] [Abstract][Full Text] [Related]
7. Harnessing autoimmunity (vitiligo) to treat melanoma: a myth or reality?
Ram M; Shoenfeld Y
Ann N Y Acad Sci; 2007 Sep; 1110():410-25. PubMed ID: 17911456
[TBL] [Abstract][Full Text] [Related]
8. Melanoma-associated leukoderma.
Hale EK; Konstadt JW
Dermatol Online J; 2003 Oct; 9(4):20. PubMed ID: 14594593
[TBL] [Abstract][Full Text] [Related]
9. Autoimmune aspects of vitiligo.
Kemp EH; Waterman EA; Weetman AP
Autoimmunity; 2001; 34(1):65-77. PubMed ID: 11681494
[TBL] [Abstract][Full Text] [Related]
10. Melanoma-associated leukoderma - immunology in black and white?
Naveh HP; Rao UN; Butterfield LH
Pigment Cell Melanoma Res; 2013 Nov; 26(6):796-804. PubMed ID: 24010963
[TBL] [Abstract][Full Text] [Related]
11. Direct evidence to support the role of antigen-specific CD8(+) T cells in melanoma-associated vitiligo.
Le Gal FA; Avril MF; Bosq J; Lefebvre P; Deschemin JC; Andrieu M; Dore MX; Guillet JG
J Invest Dermatol; 2001 Dec; 117(6):1464-70. PubMed ID: 11886510
[TBL] [Abstract][Full Text] [Related]
12. Unraveling the complex relationship between cancer immunity and autoimmunity: lessons from melanoma and vitiligo.
Uchi H; Stan R; Turk MJ; Engelhorn ME; Rizzuto GA; Goldberg SM; Wolchok JD; Houghton AN
Adv Immunol; 2006; 90():215-41. PubMed ID: 16730265
[TBL] [Abstract][Full Text] [Related]
13. Mutant HSP70 reverses autoimmune depigmentation in vitiligo.
Mosenson JA; Zloza A; Nieland JD; Garrett-Mayer E; Eby JM; Huelsmann EJ; Kumar P; Denman CJ; Lacek AT; Kohlhapp FJ; Alamiri A; Hughes T; Bines SD; Kaufman HL; Overbeck A; Mehrotra S; Hernandez C; Nishimura MI; Guevara-Patino JA; Le Poole IC
Sci Transl Med; 2013 Feb; 5(174):174ra28. PubMed ID: 23447019
[TBL] [Abstract][Full Text] [Related]
14. Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis.
Teulings HE; Limpens J; Jansen SN; Zwinderman AH; Reitsma JB; Spuls PI; Luiten RM
J Clin Oncol; 2015 Mar; 33(7):773-81. PubMed ID: 25605840
[TBL] [Abstract][Full Text] [Related]
15. Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy.
Okamoto T; Irie RF; Fujii S; Huang SK; Nizze AJ; Morton DL; Hoon DS
J Invest Dermatol; 1998 Dec; 111(6):1034-9. PubMed ID: 9856813
[TBL] [Abstract][Full Text] [Related]
16. Hypopigmentation, vitiligo, and melanoma. New data, more enigmas.
Nordlund JJ
Arch Dermatol; 1987 Aug; 123(8):1005-8. PubMed ID: 3631979
[No Abstract] [Full Text] [Related]
17. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy.
Rosenberg SA; White DE
J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):81-4. PubMed ID: 8859727
[TBL] [Abstract][Full Text] [Related]
18. [Malignant melanoma, leukoderma and vitiligo].
Kraus L; Landthaler M
Z Hautkr; 1980 Feb; 55(4):218-31. PubMed ID: 6996365
[TBL] [Abstract][Full Text] [Related]
19. Melanoma-associated leukoderma and vitiligo cannot be differentiated based on blinded assessment by experts in the field.
Lommerts JE; Teulings HE; Ezzedine K; van Geel N; Hartmann A; Speeckaert R; Spuls PI; Wolkerstorfer A; Luiten RM; Bekkenk MW
J Am Acad Dermatol; 2016 Dec; 75(6):1198-1204. PubMed ID: 27717621
[TBL] [Abstract][Full Text] [Related]
20. Vitiligo and malignant melanoma: a significant association?
Gregor RT
S Afr Med J; 1976 Aug; 50(3F):1447-9. PubMed ID: 973163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
